Stockreport

Evidence Supporting Combined Use of Deucrictibant IR with Deucrictibant XR Presented at CIIC Spring 2026 Conference [Yahoo! Finance]

Pharvaris N.V. - Ordinary Shares  (PHVS) 
PDF novel, oral bradykinin B2 receptor antagonists to help address unmet needs of those living with bradykinin-mediated diseases such as hereditary angioedema (HAE) and acqu [Read more]